A presidential health expert on Biden's prostate cancer diagnosis

No public evidence suggests Biden's doctors mishandled prostate cancer testing, writes physician and former reporter Lawrence K. Altman.

May 19, 2025 Check out STAT+

Sponsored By

ROBERTO SCHMIDT/AFP via Getty Images Opinion: I've reported on presidents' health for 53 years. No public evidence suggests Biden's doctors mishandled prostate cancer testing Biden diagnosis analyzed by Lawrence K. Altman, a physician, and former New York Times reporter who has covered presidential health for decades. By Lawrence K. Altman STAT+ | Scientists are pushing to get their grants reinstated — and some are winning Grant termination letters say there are no appeals, but dozens of appeals have succeeded as researchers lobby and sue to restore funding. By Elizabeth Cooney Trump's science adviser calls for return to 'gold-standard' research to kickstart stalled advances Trump science adviser Michael Kratsios calls for transparency in research, revival of scientific innovation, change in how science is funded By Jonathan Wosen Photo illustration: Christine Kao/STAT; Screen Capture via Youtube STAT+ | Inside the rise of Tracy Beth Høeg, the Covid contrarian shaping FDA vaccine policy Høeg has been skeptical of the safety and value of some vaccines, raising questions about how the FDA will approach them. By Lizzy Lawrence Opinion: The end to animal testing marks the beginning of better biomedicine Animals do not offer a predictive model for drug interactions with human physiology. If anything, they have held biomedicine back. By Ellen P. Carlin and Jason Paragas Opinion: There is no replacement (yet) for animal models in medical research Despite a recent NIH announcement, animal models are becoming even more important because of recent breakthroughs in single-cell biology. By Carole LaBonne Sarah Gonzales for STAT UnitedHealth said it was too dangerous for him to be discharged. Days later, it denied his care At a STAT Summit, discussion of health insurers' use of algorithms to predict how long patients need intense care — and how that affects families. By Angus Chen STAT+ | Regeneron to buy 23andMe out of bankruptcy for $256 million The biotech said it would buy 23andMe out of bankruptcy, potentially bringing to a close the saga of the genetic testing company. By Matthew Herper

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser